Impact of hepatitis A vaccination of Indigenous children on notifications of hepatitis A in north Queensland.
نویسندگان
چکیده
OBJECTIVE To describe the impact of a hepatitis A vaccination program for Indigenous children in north Queensland. DESIGN Enhanced surveillance of all notified cases of hepatitis A in north Queensland from 1996 to 2003. SETTING North Queensland; population, 596 500 people, including about 6900 Indigenous children aged under five years. INTERVENTIONS Hepatitis A vaccine was provided to Indigenous children in north Queensland from February 1999; two doses were recommended (at 18 months and 2 years of age), as was catch-up vaccination up to the sixth birthday. RESULTS In the 4 years 1996-1999, 787 cases of hepatitis A were notified in north Queensland, 237 (30%) of which were in Indigenous people. The average annual notification rates in Indigenous and non-Indigenous people during this period were 110 and 25 cases per 100 000 persons, respectively. In the first 4 years after introduction of the vaccination program (2000-2003), 66 cases of hepatitis A were notified. Only nine of the 66 (14%) were in Indigenous people. The average annual notification rates in Indigenous and non-Indigenous people in 2000-2003 were 4 and 2.5 cases per 100 000 persons, respectively. CONCLUSION Hepatitis A seems to have been eradicated from Indigenous communities in north Queensland very soon after the vaccination program began. The rapid decline in notifications in non-Indigenous as well as Indigenous people suggests the program quickly interrupted chains of transmission from Indigenous children to the broader community. To our knowledge this is the first evidence that a hepatitis A vaccination program targeting a high-risk population within a community can reduce disease in the broader community. Hepatitis A vaccine should be provided to other high-risk Indigenous children elsewhere in Australia.
منابع مشابه
Status of Hepatitis B Immunization in Medical Stuffs at Children Medical Center Hospital-Tehran
Introduction: Hepatitis B is a disease caused by the hepatitis B virus (HBV), which is transmitted through percutaneous (i.e., puncture through the skin) or mucosal (i.e., direct contact with mucous membranes) exposure to infectious blood or body fluids. HBV can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. Persons with chronic infection a...
متن کاملPersistence of immunity to hepatitis B vaccine as infants, 17 years earlier
Background: In Iran scince 1992, hepatitis B vaccination was a part of the national vaccination program. Hepatitis B vaccination is effective in the epidemiology of hepatitis B. The aim ofthis study was to evaluate the long – term persistence of immunity. Methods: This cross-sectional analytical study was conducted on children and adolescents aged between 6-18 years in Birjand, who recei...
متن کاملHepatitis B vaccine immunogenicity in Kerman 12 months infants
Introduction: Infection with HBV is the most common chronic viral infection and mortality in children. Prevention of this infection with vaccination is vital. This study was done to compare the antibody level in post hepatitis B vaccination in children with 12 months age. Materials and Methods:This descriptive study was carreid out on healthy 120 children ...
متن کاملStatus of Hepatitis B Immunization in Medical Stuffs at Children Medical Center Hospital-Tehran
Introduction: Hepatitis B is a disease caused by the hepatitis B virus (HBV), which is transmitted through percutaneous (i.e., puncture through the skin) or mucosal (i.e., direct contact with mucous membranes) exposure to infectious blood or body fluids. HBV can cause chronic infection, resulting in cirrhosis of the liver, liver cancer, liver failure, and death. Persons with chronic infection a...
متن کاملImmunity to Hepatitis B Vaccine in Thalassaemic Patients based on the Time Passed from Vaccination
Background & Aims: Hepatitis B virus is one of the causes of acute and chronic hepatitis. Due to multiple hospitalization and blood transfusion, thalassaemic patients are at higher risk of this infection. Duration of the immunity after vaccination in this high-risk group and the need for booster vaccination is uncertain. The aim of this study was to find antibody titration and immunity to Hepat...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- The Medical journal of Australia
دوره 181 9 شماره
صفحات -
تاریخ انتشار 2004